Kidney issues, access to innovation, rare disease issues, organ rejection
2026 · 3rd Quarter (July 1 - Sep 30)
HANSA BIOPHARMA
Filed by TARPLIN, DOWNS & YOUNG, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Termination
- Posted
- Oct 20, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- TARPLIN, DOWNS & YOUNG, LLC
- Client
- HANSA BIOPHARMA
- Filing UUID
- 39404bd2-7d30-4e2a-8905-e2b26e73ba1f
- Termination date
- Aug 31, 2026
Literal source text
Lobbying issues and bill citations
Federal budget issues
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.